NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

You might also be interested in reading Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B.